National Collaborating Centre for Women's and Children's Health (UK). NICE Clinical Guidelines, No. 107. Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy. London: RCOG Press, Aug 2010.
WHO Guidelines Approved by the Guidelines Review Committee. WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia. World Health Organization: Geneva, 2011.
American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122: 1122-1131.
Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P; SOGC Hypertension Guideline Committee. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: Executive summary. JObstetGynaecol Can 2014; 36: 416-441.
Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, Zeeman GG, Brown MA. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens 2014; 4: 97-104.
Sanderson M, Sappenfield WM, Jespersen KM, Liu Q, Baker SL. Association between level of delivery hospital and neonatal outcomes among South Carolina Medicaid recipients. Am J Obstet Gynecol 2000; 183: 1504-1511.
Bode MM, O'Shea TM, Metzguer KR, Stiles AD. Perinatal regionalization and neonatal mortality in North Carolina, 1968-1994. Am J Obstet Gynecol 2001; 184: 1302-1307.
Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VK, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658.
Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683.
Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, Bujold E, Goncalves L, Gomez R, Edwin S, Mazor M. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17: 3-18.
Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992-1005.
Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007; 197: 244.e1-8.
Wallner W, Sengenberger R, Strick R, Strissel PL, Meurer B, Beckmann MW, Schlembach D. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (London) 2007; 112: 51-57.
Wikström AK, Larsson A, Eriksson UJ, Nash P, Nordén- Lindeberg S, Olovsson M. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol 2007; 109: 1368-1374.
Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, Chaiworapongsa T, Levine RJ, Karumanchi SA. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008; 21: 9-23.
Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E,Mazaki-Tovi S, Gotsch F, Edwin SS, Gomez R, Yeo L, Conde-Agudelo A, Hassan SS. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009; 22: 1021-1038.
Romero R, Chaiworapongsa T, Erez O, Tarca AL, GervasiMT, Kusanovic JP, Mittal P, Ogge G, Vaisbuch E, Mazaki-Tovi S, Dong Z, Kim SK, Yeo L, Hassan SS. An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: Results of a longitudinal study. J Matern Fetal Neonatal Med 2010; 23: 1384-1399.
Schiettecatte J, Russcher H, Anckaert E, Mees M, Leeser B, Tirelli AS, Fiedler GM, Luthe H, Denk B, Smitz J. Multicenter evaluation of the first automated Elecsys sFlt-1 and plGF assays in normal pregnancies and preeclampsia. Clin Biochem 2010, 43: 768-770.
Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H. An automated method for the determination of the sFlt-1/PlGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010; 202: 161.e1-11.
Kaufmann I, Rusterholz C, Hösli I, Hahn S, Lapaire O. Can detection of late-onset PE at triage by sFlt-1 or PlGF be improved by the use of additional biomarkers. Prenat Diagn 2012; 32: 1288-1294.
Leañ os-Miranda A, Campos-Galicia I, Isordia-Salas I, Rivera-Leañ os R, Romero-Arauz JF, Ayala-Méndez JA, Ulloa-Aguirre A. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia. J Hypertens 2012; 30: 2173-2181.
Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125: 911-919.
Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, Calda P, Holzgreve W, Galindo A, Engels T, Denk B, Stepan H. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012; 206: 58.e1-8.
Hassan MF, Rund NMA, Salama AH. An elevated maternal plasma soluble fms-like tyrosine kinase-1 to placental growth factor ratio at midtrimester is a useful predictor for preeclampsia. Obstet Gynecol Int 2013; 2013: 202346. Epub 2013 Dec 4.
Holmes VA, Young IS, Paterson CC, Maresh MJA, Pearson DWM, Walker JD, McCane DR, for the Diabetes and Preeclampsia Intervention Trial (DAPIT) Study Group. The role of angiogenic and antiangiogenic factors in the second trimester in the prediction of preeclampsia in pregnant women with type 1 diabetes. Diabetes Care 2013; 36: 3671-3677.
Teixeira PG, Reis ZS, Andrade SP, Rezende CA, Lage EM, Velloso EP, Santana CA, Cabral AC. Presymptomatic prediction of preeclampsia with angiogenic factors, in high risk pregnant women. Hypertens Pregnancy 2013; 32: 312-320.
Alahakoon TI, Zhang W, Trudinger BJ, Lee VW. Discordant clinical presentations of preeclampsia and intrauterine fetal growth restrictionwith similar pro- and anti-angiogenic profiles. J Matern Fetal Neonatal Med 2014; 27: 1854-1859.
Forest JC, Thériault S, Massé J, Bujold E, Giguère Y. Soluble Fms-like tyrosine kinase-1 to placental growth factor ratio in mid-pregnancy as a predictor of preterm preeclampsia in asymptomatic pregnant women. Clin Chem LabMed 2014; 52: 1169-1178.
Herraiz I, Dröge LA, Gómez-Montes E, Henrich W, Galindo A, Verlohren S. Characterization of the soluble fms-like tyrosine kinase-1 to placental growth factor ratio in pregnancies complicated by fetal growth restriction. Obstet Gynecol 2014; 124: 265-273.
Pinheiro CC, Rayol P, Gozzani L, Machado dos Reis L, Zampieri G, Bitencourt Dias C, Woronik V. The relationship of angiogenic factors to maternal and neonatal manifestations of early-onset and late-onset preeclampsia. Prenat Diagn 2014; 34: 1084-1092.
Zhang J, Klebanoff MA, Roberts JM. Prediction of adverse outcomes by common definitions of hypertension in pregnancy. Obstet Gynecol 2001; 97: 261-267.
Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, Dong Z, Tarca A, Gaurav B, Hassan SS. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011; 24: 1187-1207.
Schaarschmidt W, Rana S, Stepan H. The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome. J PerinatMed 2013; 41: 511-516.
Chaiworapongsa T, Romero R, Korzeniewski SJ, Kusanovic JP, Soto E, Lam J, Dong Z, Than NG, Yeo L, Hernandez-Andrade E, Conde-Agudelo A, Hassan SS. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol 2013; 208: 287.e1-287.
Chaiworapongsa T, Romero R, Korzeniewski SJ, Cortez JM, Pappas A, Tarca AL, Chaemsaithong P, Dong Z, Yeo L, Hassan SS. Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting suspected preeclampsia to the obstetrical triage area: A prospective study. J Matern Fetal Neonatal Med 2014; 27: 132-144.
Schoofs K, Grittner U, Engels T, Pape J, Denk B, Henrich W, Verlohren S. The importance of repeated measurements of the sFlt-1/PlGF ratio for the prediction of preeclampsia and intrauterine growth restriction. J PerinatMed 2014; 42: 61-68.
Gómez-Arriaga PI, Herraiz I, López-Jiménez EA, Escribano D, Denk B, Galindo A. Uterine artery Doppler and sFlt-1/PlGF ratio: Prognostic value in early-onset preeclampsia. Ultrasound Obstet Gynecol 2014; 43: 525-532.
Schlembach D, Wallner W, Sengenberger R, Stiegler E, Mörtl M, Beckmann MW, Lang U. Angiogenic growth factor levels in maternal and fetal blood: Correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2007; 29: 407-413.
Chaiworapongsa T, Espinoza J, Gotsch F, Kim YM, Kim GJ, Goncalves LF, Edwin S, Kusanovic JP, Erez O, Than NG, Hassan SS, Romero R. The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med 2008; 21: 25-40.
Petzold K, Jank A, Faber R, Stepan H. Relation between maternal angiogenic factors and utero-placental resistance in normal first- and second-trimester pregnancies. Hypertens Pregnancy 2011; 30: 401-407.
Soto E, Romero R, Kusanovic JP, Ogge G, Hussein Y, Yeo L, Hassan SS, Kim CJ, Chaiworapongsa T. Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med 2012; 25: 498-507.
Gómez-Arriaga PI, Herraiz I, López-Jiménez EA, Gómez-Montes E, Denk B, Galindo A. Uterine artery Doppler and sFlt-1/PlGF ratio: Usefulness in diagnosis of preeclampsia. Ultrasound Obstet Gynecol 2013; 41: 530-537.
Lobmaier SM, Figueras F, Mercade I, Perello M, Peguero A, Crovetto F, Ortiz JU, Crispi F, Gratacós E. Angiogenic factors vs Doppler surveillance in the prediction of adverse outcome among late-pregnancy small-for-gestational-age fetuses. Ultrasound Obstet Gynecol 2014; 43: 533-540.
Espinoza J, Romero R, Nien JK, Gomez R, Kusanovic JP, Gonçalves LF, Medina L, Edwin S, Hassan S, Carstens M, Gonzalez R. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 2007; 196: 326.e1-13.
Stepan H, Unversucht A,Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007; 49: 818-824.
Diguisto C, Le Gouge A, Piver E, Giraudeau B, Peerotin F. Second-trimester uterine artery Doppler, PlGF, sFlt-1, sEndoglin, and lipid-related markers for predicting preeclampsia in a high-risk population. Prenat Diagn 2014; 33: 1070-1074.
Kulmala L, Phupong V. Combination of plasma-soluble fms-like tyrosine kinase 1 and uterine artery Doppler for the prediction of preeclampsia in cases of elderly gravida. Hypertension Res 2014; 37: 538-542.
Stubert J, Ullmann S, BolzM, Külz T, Dieterich M, Richter DU, Reimer T. Prediction of preeclampsia and induced delivery at <34 weeks gestation by sFLT-1 and PlGF in patients with abnormal midtrimester uterine Doppler velocimetry: A prospective cohort analysis BMC Pregnancy Childbirth 2014 14 292 49
Verlohren S, Stepan H, Dechend R. Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. Clin Sci 2012; 122: 43-52.
Garcia-Tizon Larroca S, Tayyar A, Poon LC, Wright D, Nicolaides KH. Competing risks model in screening for preeclampsia by biophysical and biochemical markers at 30-33 weeks' gestation. Fetal Diagn Ther 2014; 36: 9-17.
Hirashima C, Ohkuchi A, Takahashi K, Suzuki H, Matsubara S, Suzuki M. A novel three-step approach for predicting imminent onset of preeclampsia within 4 weeks after blood sampling at 19-31 weeks of gestation. Hypertension Res 2014; 37: 519-525.
Lai J, Garcia-Tizon Larroca S, Peeva G, Poon LC, Wright D, Nicolaides KH. Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation. Fetal Diagn Ther 2014; 35: 240-248.
German guideline. Available at: Http://www.awmf.org/uploads/ tx-szleitlinien/015-018l-S1-Diagnostik-Therapie-hypertensiver -Schwangerschaftserkrankungen-2014-01.pdf [Accessed January 2015].
Ohkuchi A, Hirashima C, Suzuki H, Takahashi K, Yoshida M, Matsubara S, Suzuki M. Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. Hypertens Res 2010; 33: 422-427.
Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, Sabria J,Markfeld-Erol F, Galindo A, Schoofs K, Denk B, Stepan H. New gestational phase-specific cut-off values for the use of soluble fms-like tyrosine kinase-1/placental growth factor ratio as diagnostic test for preeclampsia. Hypertension 2014; 63: 346-352.
Hund M, Schoedl M, Dilba P, Verhagen-Kamerbeek W, Stepan H. Multicenter prospective clinical study to evaluate the prediction of short-term outcome in pregnant women with suspected preeclampsia (PROGNOSIS): Study protocol. BMC Pregnancy Childbirth 2014; 14: 324.
Zeisler H, Llurba E, Chantraine F,VatishM, Staff A, Sennström M, Olovsson M, Brennecke S, Stepan H, Allegranza D, Dilba P, Schoedl M, Hund M, Verlohren S. Prediction of Short-Term Outcome in Pregnant Women with Suspected Preeclampsia: The PROGNOSIS Study. COGI 2014, Paris. Abstract P79. Available at: Http://www.congressmed. com/cogi/images/pdf/COGIParisAbstractBook.pdf. [Accessed January 2015].
Strauss C, Ossada V, Hoffmann J, Stepan H. Implementierung der "neuen" cut-offs des sFlt-1/PlGF-Quotienten in die klinische Praxis [Implementation of the new cut-offs of the sFlt-1/PlGF ratio into clinical practice]. Z Geburtsh Neonatol 2014; 218: A1.
